EECP (Enhanced External Counter Pulsation) benefits sustained at two years:
This article was originally published in Clinica
Executive Summary
Vasomedical says that data is now available to show that the reduction in angina achieved using its Enhanced External Counter Pulsation (EECP) therapy is sustained at two years. The results come from an analysis of 254 patients from an International EECP patient registry at the University of Pittsburgh Graduate School of Public Health in Pennsylvania. Before EECP therapy, 80% of patients had severe angina. This figure fell to 16% immediately following treatment and remained at this level for the next two years, says the Westbury, New York firm.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.